AIMS: Survival and response rates in metastatic colorectal cancer remain poor, despite advances in drug development. There is increasing evidence to suggest that gender-specific differences may contribute to poor clinical outcome. We tested the hypothesis that genomic profiling of metastatic colorectal cancer is dependent on gender. MATERIALS & METHODS: A total of 152 patients with metastatic colorectal cancer who were treated with oxaliplatin and continuous infusion 5-fluorouracil were genotyped for 21 polymorphisms in 13 cancer-related genes by PCR. Classification and regression tree analysis tested for gender-related association of polymorphisms with overall survival, progression-free survival and tumor response. RESULTS: Classification and regression tree analysis of all polymorphisms, age and race resulted in gender-specific predictors of overall survival, progression-free survival and tumor response. Polymorphisms in the following genes were associated with gender-specific clinical outcome: estrogen receptor β, EGF receptor, xeroderma pigmentosum group D, voltage-gated sodium channel and phospholipase A2. CONCLUSION: Genetic profiling to predict the clinical outcome of patients with metastatic colorectal cancer may depend on gender.
AIMS: Survival and response rates in metastatic colorectal cancer remain poor, despite advances in drug development. There is increasing evidence to suggest that gender-specific differences may contribute to poor clinical outcome. We tested the hypothesis that genomic profiling of metastatic colorectal cancer is dependent on gender. MATERIALS & METHODS: A total of 152 patients with metastatic colorectal cancer who were treated with oxaliplatin and continuous infusion 5-fluorouracil were genotyped for 21 polymorphisms in 13 cancer-related genes by PCR. Classification and regression tree analysis tested for gender-related association of polymorphisms with overall survival, progression-free survival and tumor response. RESULTS: Classification and regression tree analysis of all polymorphisms, age and race resulted in gender-specific predictors of overall survival, progression-free survival and tumor response. Polymorphisms in the following genes were associated with gender-specific clinical outcome: estrogen receptor β, EGF receptor, xeroderma pigmentosum group D, voltage-gated sodium channel and phospholipase A2. CONCLUSION: Genetic profiling to predict the clinical outcome of patients with metastatic colorectal cancer may depend on gender.
Authors: Scott P Fraser; James K J Diss; Athina-Myrto Chioni; Maria E Mycielska; Huiyan Pan; Rezan F Yamaci; Filippo Pani; Zuzanna Siwy; Monika Krasowska; Zbigniew Grzywna; William J Brackenbury; Dimis Theodorou; Meral Koyutürk; Handan Kaya; Esra Battaloglu; Manuela Tamburo De Bella; Martin J Slade; Robert Tolhurst; Carlo Palmieri; Jie Jiang; David S Latchman; R Charles Coombes; Mustafa B A Djamgoz Journal: Clin Cancer Res Date: 2005-08-01 Impact factor: 12.531
Authors: Kamatham A Naidu; Aejaz Nasir; Haim Pinkas; Hans E Kaiser; Patric Brady; Domenico Coppola Journal: In Vivo Date: 2003 Sep-Oct Impact factor: 2.155
Authors: Oliver A Press; Wu Zhang; Michael A Gordon; Dongyun Yang; Georg Lurje; Syma Iqbal; Anthony El-Khoueiry; Heinz-Josef Lenz Journal: Cancer Res Date: 2008-04-15 Impact factor: 12.701
Authors: Arantza Fariña Sarasqueta; Gesina van Lijnschoten; Valery E P P Lemmens; Harm J T Rutten; Adriaan J C van den Brule Journal: Mol Diagn Ther Date: 2011-10-01 Impact factor: 4.074
Authors: Michael N Passarelli; Amanda I Phipps; John D Potter; Karen W Makar; Anna E Coghill; Karen J Wernli; Emily White; Andrew T Chan; Carolyn M Hutter; Ulrike Peters; Polly A Newcomb Journal: Cancer Res Date: 2012-11-13 Impact factor: 12.701
Authors: Anja Rudolph; Hong Shi; Asta Försti; Michael Hoffmeister; Juan Sainz; Lina Jansen; Kari Hemminki; Hermann Brenner; Jenny Chang-Claude Journal: BMC Cancer Date: 2014-11-07 Impact factor: 4.430